Article Versions Notes

Kovács ZM, Óvári J, Dienes C, Magyar J, Bányász T, Nánási PP, Horváth B, Feher A, Varga Z, Szentandrássy N. Correction: Kovács et al. ABT-333 (Dasabuvir) Increases Action Potential Duration and Provokes Early Afterdepolarizations in Canine Left Ventricular Cells via Inhibition of I_Kr. Pharmaceuticals 2023, 16, 488. Pharmaceuticals. 2024; 17(9):1137. https://doi.org/10.3390/ph17091137

Kovács, Zsigmond Máté, József Óvári, Csaba Dienes, János Magyar, Tamás Bányász, Péter P. Nánási, Balázs Horváth, Adam Feher, Zoltan Varga, and Norbert Szentandrássy. 2024. "Correction: Kovács et al. ABT-333 (Dasabuvir) Increases Action Potential Duration and Provokes Early Afterdepolarizations in Canine Left Ventricular Cells via Inhibition of I_Kr. Pharmaceuticals 2023, 16, 488" Pharmaceuticals 17, no. 9: 1137. https://doi.org/10.3390/ph17091137

Kovács, Z. M., Óvári, J., Dienes, C., Magyar, J., Bányász, T., Nánási, P. P., Horváth, B., Feher, A., Varga, Z., & Szentandrássy, N. (2024). Correction: Kovács et al. ABT-333 (Dasabuvir) Increases Action Potential Duration and Provokes Early Afterdepolarizations in Canine Left Ventricular Cells via Inhibition of I_Kr. Pharmaceuticals 2023, 16, 488. Pharmaceuticals, 17(9), 1137. https://doi.org/10.3390/ph17091137